PA
ADMA icon

Profund Advisors’s ADMA Biologics ADMA Stock Holding History

Profund Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$989K Sell
118,110
-5,972
-5% -$54.4K 0.03% 354
2026
Q1 		$1.12M Buy
124,082
+8,567
+7% +$135K 0.04% 321
2025
Q4 		$2.11M Buy
115,515
+31,047
+37% +$523K 0.06% 206
2025
Q3 		$1.24M Buy
84,468
+19,697
+30% +$338K 0.04% 283
2025
Q2 		$1.18M Buy
64,771
+9,576
+17% +$195K 0.04% 264
2025
Q1 		$1.1M Sell
55,195
-51,232
-48% -$886K 0.05% 276
2024
Q4 		$1.83M Buy
106,427
+20,215
+23% +$380K 0.07% 193
2024
Q3 		$1.72M Buy
86,212
+32,029
+59% +$498K 0.07% 216
2024
Q2 		$606K Sell
54,183
-53,803
-50% -$451K 0.02% 442
2024
Q1 		$713K Buy
107,986
+16,913
+19% +$92.4K 0.03% 456
2023
Q4 		$412K Sell
91,073
-16,080
-15% -$59.5K 0.02% 619
2023
Q3 		$384K Sell
107,153
-24,556
-19% -$94.5K 0.02% 549
2023
Q2 		$486K Sell
131,709
-50,704
-28% -$188K 0.03% 522
2023
Q1 		$604K Buy
+182,413
New +$631K 0.04% 450

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Profund Advisors's ADMA Position: Q2 2026 in Review

Profund Advisors reduced its ADMA Biologics (ADMA) stake by 4.8% in Q2 2026, selling an estimated $54.4K and leaving 118,110 shares worth $989K. The position accounts for 0.03% of the portfolio, ranked #354.

Profund Advisors first reported a position in ADMA in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.11M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Profund Advisors held 118,110 shares of ADMA Biologics worth $989K as of Q2 2026.
  • Profund Advisors sold 5,972 ADMA Biologics shares in Q2 2026, an estimated $54.4K.
  • ADMA Biologics made up 0.03% of Profund Advisors's portfolio in Q2 2026, its #354 holding.
  • Profund Advisors first reported a position in ADMA Biologics in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's ADMA Biologics position peaked at $2.11M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.